TOCILIZUMAB IN THE TREATMENT OF CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS: ANALYSIS OF FACTORS INFLUENCING THE THERAPY EFFICIENCY IN THE LONG TERM
The introduction of tocilizumab - a drug that blocks interleukin 6 - into the practice of pediatric rheumatologists is an important achievement in the treatment of systemic juvenile arthritis (SJA). Objective: Our aim was to identify factors associated with the level of treatment response and safety...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
"Paediatrician" Publishers LLC,
2015-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |